Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors
about
Application of nucleoside analogues to liver transplant recipients with hepatitis BAntibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donorsUtilization of expanded criteria donors in liver transplantation.Cadaver donor screening for infectious agents in solid organ transplantation.Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation.Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers.An unusual cause of elevated values on liver function tests in a liver transplant patient.Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage?Hepatitis B: progress in the last 15 years.Use of hepatitis B core antibody-positive donors for liver transplantation.Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers.Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool.Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region.Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.Review article: hepatitis B and liver transplantation.PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantationChanging pattern of donor selection criteria in deceased donor liver transplant: a review of literature.Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis.The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.Maximizing Donors with Viral hepatitis in the Current Era.Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation.Viral hepatitis in solid organ transplantation.Screening of donor and recipient in solid organ transplantation.Positive suggestions about the anti-HBc positive donor.Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.Transmission of hepatitis B infection from hepatitis B core antibody--positive livers: background and prevention.Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties.Safe use of livers from donors with positive hepatitis B core antibody.Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination.De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients.Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation.Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.Hepatitis B virus DNA in blood donors with anti-HBc as a possible indicator of active hepatitis B virus infection in Yucatan, Mexico.Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor.
P2860
Q26859796-D07F3D04-C668-4886-8810-0C0F7D938B53Q28344359-255A9BF6-F56E-4598-AB8B-08DA0F0B2A78Q33871968-FB6BAA53-488C-4369-A26F-4A7D69B8DDACQ34052592-888DF9EF-FBE3-4A61-BC88-9AE5F0E55AC3Q34255573-D07E0877-477C-4F2A-A213-73A02DBE8B80Q34365421-992708E9-B445-4E87-A8B7-FC2CFC404CC4Q34555551-D70B9634-76B4-4261-878D-4DC60CB63014Q34917705-C0DCB0A0-6CC5-4ADB-8955-4AD9F1E3C347Q34936238-DF9F0A3D-FFC0-496F-B51F-F4C3DA688B3DQ34936283-64B3DE4D-8DCB-4D10-93A1-6BA26E4DDECCQ34959703-9E3174A5-6CDA-497B-AAF0-E85AC8BC567AQ35180107-CCD0EAF8-BEDA-4140-B3E5-FE6DCA709299Q35195474-F02B47BA-8230-452B-A833-835620AC1D8DQ35715908-BE4BFF13-5EA5-4152-89CA-FE10F357FA35Q36028324-FA20FC24-7FD0-41FC-A2F0-589E322AB1C4Q36447557-CE745B1B-34D1-4486-9A73-5F3FA2F49C41Q36909187-0EF985F5-934D-417F-A318-FE6B255193ECQ37613628-55381B4D-2F6C-4DE6-B90B-DA73C0F5935EQ37842669-CDCDFEA0-B792-410B-BA04-F16DEDEFF0C9Q37870833-9DC5ECD8-8F34-42FC-89CA-133AD11EA1CBQ39116834-404EDA29-CC1C-4885-90EF-3EFCBFEAA85FQ40068166-0D2ABBEB-096B-43A8-9A79-F758D04DB6D5Q40405411-9E3D930E-A815-4CEA-9D97-F58D70E82893Q40629471-D5DA7ACE-F749-4EFF-9423-A9F6C9AC78E8Q42223313-8A78E715-8D5E-4FB2-AC80-F34960A2FF11Q42272319-98C6B99F-4B3E-470B-A2CC-047556B637DAQ42272365-8DEE96D7-27FC-4F1B-90AE-444BCD046759Q43006521-AF48E797-CC46-426F-9531-330CEA7ACCB1Q43666871-AA04AC5A-E5C3-4EE1-958D-120212C0CD6DQ43666875-434D882A-54CA-4E00-A8F8-23F1A112A8D4Q43899938-E9D931FE-0674-4E43-8DAC-D42334FCB090Q44011089-81B57CB3-6513-4924-B8B2-C8B67C990DBFQ45047969-068ACD09-7499-44CF-9090-213CFB9298AAQ45333184-FF6536C0-800D-4412-9362-69DBF6D9BFE9Q45408268-F808ACA1-693D-484C-81DE-8D242733431FQ45411000-5BD814B1-AC07-4CD4-9424-A7FECD577A6FQ45414817-6351F00A-8358-4D58-9FF0-7A0BBC2377D6Q45421748-AF9DC0C7-0A84-4EF4-829F-8CE8B01D61CCQ45423555-2ACA58B7-7723-453A-80B6-F49C6FE316F3Q46964102-7031E8A3-7F6A-4AAA-99FD-7F427C51BB17
P2860
Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@ast
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@en
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@nl
type
label
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@ast
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@en
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@nl
prefLabel
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@ast
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@en
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@nl
P2093
P1433
P1476
Prevention of de novo hepatiti ...... from anti-HBc positive donors
@en
P2093
C A Bonham
D A Geller
S F Dodson
T V Cacciarelli
P304
P356
10.1097/00007890-199910150-00028
P407
P577
1999-10-15T00:00:00Z